Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.60 |
| ▸ | MMP2 | P08253 | 7/20 | 0.60 |
| ▸ | MMP1 | P03956 | 5/20 | 0.60 |
| ▸ | MMP9 | P14780 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29677688 | 0.98 | MMP13 (0.59) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL29050259 | 0.84 | MMP1 (0.44) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL22763324 | 0.81 | CNR2 (0.46) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL31240452 | 0.80 | MMP1 (0.48) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL1244889 | 0.79 | MMP1 (0.53) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL1810844 | 0.79 | RAB9A (0.57) | MMP13MMP1ALDH1A1KDM4E | |
| SCHEMBL3550333 | 0.79 | MMP13 (0.50) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| SCHEMBL1431231 | 0.78 | MMP13 (0.59) | MMP13MMP2MMP1MMP9L3MBTL1 | |
| Hydrochloric Acid SCHEMBL10785952 | 0.78 | RAB9A (0.60) | MMP13MMP1ALDH1A1KDM4E | |
| SCHEMBL16057689 | 0.78 | MMP13 (0.49) | MMP13MMP2MMP1MMP9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200385371-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2020-12-10 | — | — | US | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| CN-102596910-A | Androgen receptor modulating compounds | ORION CORP | 2012-07-18 | — | — | CN | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| CN-1278820-A | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase | GLAXO GROUP LTD (GB) | 2001-01-03 | — | — | CN | disclosed |
| EP-1003748-A2 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999012933-A2 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | MMP13 4461/4885MMP2 4311/4885MMP1 4607/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | MMP13 4461/4885MMP2 4311/4885MMP1 4607/4885 |
| US-20200385371-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | MMP13 4066/4885MMP2 3622/4885MMP1 4051/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MMP13 4171/4885MMP2 3388/4885MMP1 4516/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MMP13 4171/4885MMP2 3388/4885MMP1 4516/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MMP13 4171/4885MMP2 3388/4885MMP1 4516/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | MMP13 4461/4885MMP2 4311/4885MMP1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.